| Pharmaceutical Information |
| Drug Name |
Aclidinium bromide |
| Drug ID |
BADD_D00037 |
| Description |
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. |
| Indications and Usage |
Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. |
| Marketing Status |
Prescription |
| ATC Code |
R03BB05 |
| DrugBank ID |
DB08897
|
| KEGG ID |
D08837
|
| MeSH ID |
C542859
|
| PubChem ID |
11519741
|
| TTD Drug ID |
D07KHH
|
| NDC Product Code |
54893-0027; 64567-0028; 72124-002; 0310-0800 |
| Synonyms |
aclidinium bromide | (3R)-3-((hydroxy(di-2-thienyl)acetyl)oxy)-1-(3-phenoxypropyl)-1-azoniabicyclo(2.2.2)octane bromide |
|
| Chemical Information |
| Molecular Formula |
C26H30BrNO4S2 |
| CAS Registry Number |
320345-99-1 |
| SMILES |
C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-] |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
